Home >> Healthcare >> Direct Oral Anticoagulants DOACs Market

Global Direct Oral Anticoagulants (DOACs) Market Size,Trends, Growth Forecast to 2031

Category : Healthcare | Report Code : 995 | Pages : 141 | Oct 2024

Report Overview

Direct oral anticoagulants (DOACs) are a class of medications used to prevent and treat blood clots by directly inhibiting specific enzymes involved in the clotting process.They include drugs that directly target either Factor Xa (such as rivaroxaban and apixaban) or thrombin (such as dabigatran), effectively reducing the risk of conditions like deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation.

The global Direct Oral Anticoagulants (DOACs) market size is projected to grow from US$ 46270 million in 2024 to US$ 74230 million in 2030; it is expected to grow at a CAGR of 8.2% from 2024 to 2030.

Analytic Insights Hub ' newest research report, the “Direct Oral Anticoagulants (DOACs) Industry Forecast” looks at past sales and reviews total world Direct Oral Anticoagulants (DOACs) sales in 2023, providing a comprehensive analysis by region and market sector of projected Direct Oral Anticoagulants (DOACs) sales for 2024 through 2030. With Direct Oral Anticoagulants (DOACs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Direct Oral Anticoagulants (DOACs) industry.

This Insight Report provides a comprehensive analysis of the global Direct Oral Anticoagulants (DOACs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Direct Oral Anticoagulants (DOACs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Direct Oral Anticoagulants (DOACs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Direct Oral Anticoagulants (DOACs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Direct Oral Anticoagulants (DOACs).

The market for Direct Oral Anticoagulants (DOACs) has experienced significant growth over the past decade. Initially introduced as alternatives to traditional anticoagulants like warfarin, DOACs offer advantages such as fixed dosing, fewer dietary restrictions, and minimal need for regular monitoring. The rising incidence of conditions such as atrial fibrillation and venous thromboembolism, coupled with an aging population, has driven increased demand for these medications. Consequently, the market has seen a surge in both prescription volume and the number of available DOACs.

In recent years, competition among pharmaceutical companies has intensified, leading to a broader range of DOAC options and potential price fluctuations. Major players like Bayer, Pfizer, and Bristol-Myers Squibb have continually advanced their products, seeking to differentiate through efficacy, safety profiles, and patient convenience. Additionally, the market has seen innovations such as the development of reversal agents for DOACs, addressing concerns over bleeding risks and enhancing the attractiveness of these drugs to both healthcare providers and patients.

Looking forward, the DOAC market is expected to continue its upward trajectory, driven by ongoing research, expanding indications, and increased global access. Emerging markets, where chronic diseases are rising alongside economic growth, present new opportunities for expansion. However, the market will also face challenges, including regulatory hurdles, potential generic competition, and the need for ongoing clinical trials to further establish long-term safety and efficacy. Overall, the DOAC market remains dynamic, with robust prospects shaped by evolving medical needs and technological advancements.

This report presents a comprehensive overview, market shares, and growth opportunities of Direct Oral Anticoagulants (DOACs) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    Oral Factor Xa Inhibitors
    Direct Thrombin Inhibitors (DTIs)

Segmentation by Application:
    Deep Vein Thrombosis
    Pulmonary Embolism
    Atrial Fibrillation
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    Bristol Myers Squibb
    Pfizer
    Daiichi Sankyo
    Janssen Pharmaceuticals
    Bayer
    Viatris
    Boehringer Ingelheim
    Accord Healthcare
    Sandoz
    Teva Pharmaceutical
    Mylan
    Apotex
    GlaxoSmithKline

Key Questions Addressed in this Report
What is the 10-year outlook for the global Direct Oral Anticoagulants (DOACs) market?
What factors are driving Direct Oral Anticoagulants (DOACs) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Direct Oral Anticoagulants (DOACs) market opportunities vary by end market size?
How does Direct Oral Anticoagulants (DOACs) break out by Type, by Application?

Frequently Asked Questions?

Ans - The purpose of a Direct Oral Anticoagulants (DOACs) market research report is to provide data-driven insights and analysis on a Direct Oral Anticoagulants (DOACs) market. It helps businesses understand industry trends, competition, consumer behavior, market size, growth potential, and risks, supporting strategic decision-making.

Ans - Market research reports typically include both quantitative (market size, revenue, growth rates) and qualitative (trends, consumer preferences, competitive analysis) data. It often includes industry statistics, surveys, expert opinions, historical data, and future forecasts.

Ans - The forecast period typically for Direct Oral Anticoagulants (DOACs) market report spans the next 5 to 10 years. It includes projected market trends, growth opportunities, and potential challenges.

Ans - Yes, Analytic Insights Hub customization services, allowing businesses to focus on specific geographies, sectors, or market segments that are relevant to them.

Ans - The report highlights major trends such as technological innovations, consumer behavior shifts, regulatory changes, or emerging markets that may impact the industry?s growth.